Prognostic factors of liver metastases from uveal melanoma

  • Laurent KodjikianEmail author
  • Jean-Daniel Grange
  • Stéphano Baldo
  • Stéphanie Baillif
  • Justus G. Garweg
  • Michel Rivoire
Clinical Investigation



This study was designed to assess survival and identify prognostic factors for liver metastases diagnosed by systematic screening in uveal melanoma patients.


Among 602 consecutive patients treated over 10 years for uveal melanoma and followed by systematic semi-annual hepatic screening (abdominal ultrasonography), 63 (10.5%) developed liver metastases; these patients form the basis of this study. Factors including patient demographics, characteristics of the uveal tumor, metastasis-free interval, severity of liver metastatic involvement, and treatments of metastases were studied retrospectively regarding their prognostic value, using univariate (Kaplan-Meier method) and multivariate (Cox model) analyses.


Thirty-five patients (55.6% of the metastatic population) received systemic chemotherapy or best supportive care only; 14 patients (22.2% of the metastatic population) diagnosed with diffuse liver involvement had cytoreductive surgery and intra-arterial chemotherapy; 14 (22.2% of the metastatic population) had complete surgical removal of liver metastases followed by postoperative intra-arterial chemotherapy. No significant surgical complications were experienced. The median overall survival after diagnosis of liver metastases was 15 months. It reached 25 months for selected patients with complete resection (P=0.0002). In this cohort of 63 patients, ten or fewer preoperatively diagnosed metastases and primary uveal melanoma not involving the ciliary body were independently associated with better prognosis.


This study suggests that selected patients with screened liver metastases from uveal melanoma may benefit from aggressive treatment, including surgery. The two independent favorable prognostic factors are fewer than ten metastases at screening and the absence of ciliary body involvement.


Uveal melanoma Liver metastasis Surgical treatment Prognostic factors 


  1. 1.
    Aoyama T, Mastrangelo MJ, Berd D, Nathan FE, Shields CL, Shields JA, Rosato EL, Rosato FE, Sato T (2000) Protracted survival after resection of metastatic uveal melanoma. Cancer 89:1561–1568CrossRefPubMedGoogle Scholar
  2. 2.
    Bedikian AY, Kantarjian H, Young SE, Bodey GP (1981) Prognosis in metastatic choroidal melanoma. South Med J 74:574–577PubMedGoogle Scholar
  3. 3.
    Bedikian AY, Legha SS, Mavligit G, Carrasco CH, Khorana S, Plager C, Papadopoulos N, Benjamin RS (1995) Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 76:1665–1670PubMedCrossRefGoogle Scholar
  4. 4.
    Cox D (1972) Regression models and life-tables (with discussions). J R Statist Soc Series B 34:187–220Google Scholar
  5. 5.
    Eskelin S, Pyrhonen S, Hahka-Kemppinem M, Tuomaala S, Kivela T (2003) A prognostic model and staging for metastatic uveal melanoma. Cancer 97:465–475CrossRefPubMedGoogle Scholar
  6. 6.
    Gragoudas ES, Egan KM, Seddon JM, Glynn RJ, Walsh SM, Finn SM, Munzenrider JE, Spar MD (1991) Survival of patients with metastases from uveal melanoma. Ophthalmology 98:383–389; discussion 90PubMedGoogle Scholar
  7. 7.
    Gragoudas ES, Seddon JM, Egan KM, Glynn RJ, Goitein M, Munzenrider J, Verhey L, Urie M, Koehler A (1988) Metastasis from uveal melanoma after proton beam irradiation. Ophthalmology 95:992–999PubMedGoogle Scholar
  8. 8.
    Gragoudas ES, Seddon JM, Egan KM, Polivogianis L, Hsieh CC, Goitein M, Verhey L, Munzenrider J, Austin-Seymour M, Urie M et al (1986) Prognostic factors for metastasis following proton beam irradiation of uveal melanomas. Ophthalmology 93:675–680PubMedGoogle Scholar
  9. 9.
    Kaplan E, Meier P (1958) Non-parametric estimation from incomplete observation. J Am Stat Assoc 53:457–481CrossRefGoogle Scholar
  10. 10.
    Karakousis CP, Temple DF, Moore R, Ambrus JL (1983) Prognostic parameters in recurrent malignant melanoma. Cancer 52:575–579PubMedCrossRefGoogle Scholar
  11. 11.
    Kath R, Hayungs J, Bornfeld N, Sauerwein W, Hoffken K, Seeber S (1993) Prognosis and treatment of disseminated uveal melanoma. Cancer 72:2219–2223PubMedCrossRefGoogle Scholar
  12. 12.
    Kodjikian L, Roy P, Rouberol F, Chauvel P, Jean-Louis B, Garweg J, Little R, Sasco A, Grange J (2004) Survival after proton-beam irradiation of uveal melanomas. Am J Ophthalmol 137:1002–1010CrossRefPubMedGoogle Scholar
  13. 13.
    Leyvraz S, Spataro V, Bauer J, Pampallona S, Salmon R, Dorval T, Meuli R, Gillet M, Lejeune F, Zografos L (1997) Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol 15:2589–2595PubMedGoogle Scholar
  14. 14.
    Li W, Gragoudas ES, Egan KM (2000) Metastatic melanoma death rates by anatomic site after proton beam irradiation for uveal melanoma. Arch Ophthalmol 118:1066–1070PubMedGoogle Scholar
  15. 15.
    McLean IW, Foster WD, Zimmerman LE (1982) Uveal melanoma: location, size, cell type, and enucleation as risk factors in metastasis. Hum Pathol 13:123–132PubMedCrossRefGoogle Scholar
  16. 16.
    McLean IW, Foster WD, Zimmerman LE (1977) Prognostic factors in small malignant melanomas of choroid and ciliary body. Arch Ophtalmol 95:48–58Google Scholar
  17. 17.
    Oken M, Creech R, Tormey D (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655PubMedCrossRefGoogle Scholar
  18. 18.
    Patel JK, Didolkar MS, Pickren JW, Moore RH (1978) Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg 135:807–810CrossRefPubMedGoogle Scholar
  19. 19.
    Peto R, Peto J (1972) Asymptotically efficient rank invariant test procedures. J R Statist Soc Series A 135:185–206CrossRefGoogle Scholar
  20. 20.
    Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, Becher R (1996) Prognostic implications of monosomy 3 in uveal melanoma. Lancet 347:1222–1225CrossRefPubMedGoogle Scholar
  21. 21.
    Pyrhonen S (1998) The treatment of metastatic uveal melanoma. Eur J Cancer 34(Suppl 3):S27–S30PubMedCrossRefGoogle Scholar
  22. 22.
    Raivio I (1977) Uveal melanoma in Finland. An epidemiological, clinical, histological and prognostic study. Acta Ophthalmol Suppl 133:1–64PubMedGoogle Scholar
  23. 23.
    Rajpal S, Moore R, Karakousis CP (1983) Survival in metastatic ocular melanoma. Cancer 52:334–336PubMedCrossRefGoogle Scholar
  24. 24.
    Rouberol F, Roy P, Kodjikian L, Gérard J, Jean-Louis B, Grange J (2004) Survival, anatomic and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (a 15 years experience with betarays). Am J Ophthalmol 137:893–900CrossRefPubMedGoogle Scholar
  25. 25.
    Salmon RJ, Levy C, Plancher C, Dorval T, Desjardins L, Leyvraz S, Pouillart P, Schlienger P, Servois V, Asselain B (1998) Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy. Eur J Surg Oncol 24:127–130CrossRefPubMedGoogle Scholar
  26. 26.
    Seddon JM, Albert DM, Lavin PT, Robinson N (1983) A prognostic factor study of disease-free interval and survival following enucleation for uveal melanoma. Arch Ophthalmol 101:1894–1899PubMedGoogle Scholar
  27. 27.
    Seregard S (1996) Posterior uveal melanoma. The Swedish perspective. Acta Ophthalmol Scand 74:315–329PubMedCrossRefGoogle Scholar
  28. 28.
    Shammas HF, Blodi FC (1977) Prognostic factors in choroidal and ciliary body melanomas. Arch Ophthalmol 95:63–69PubMedGoogle Scholar
  29. 29.
    Shields J, Shields C (1992) Introduction to melanocytic tumors of the uvea. In: Shields J, Shields C (eds) Intraocular tumors; a text and atlas. Williams & Wilkins, PhiladelphiaGoogle Scholar
  30. 30.
    Singh AD, Wang MX, Donoso LA, Shields CL, Potter PD, Shields JA, Elston RC, Fijal B (1996) Familial uveal melanoma, III. Is the occurrence of familial uveal melanoma coincidental? Arch Ophthalmol 114:1101–1104PubMedGoogle Scholar
  31. 31.
    Sobin L, Wittekind C (2002) TNM classification of malignant tumours. 6th ed. Wiley-Liss, GenèveGoogle Scholar
  32. 32.
    The Collaborative Ocular Melanoma Study (2001) Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol 119:670–676Google Scholar
  33. 33.
    The Collaborative Ocular Melanoma Study Group (1997) Factors predictive of growth and treatment of small choroidal melanoma: COMS report no. 5. Arch Ophthalmol 115:1537–1544Google Scholar
  34. 34.
    Vidal JL, Bacin F, Albuisson E, Rozan R, Desjardins L, D’Hermies F, Grange JD, Chauvel P, Caujolle JP, Sahel J et al (1995) “Melanoma 92”. Epidemiological study of uveal melanoma in France. J Fr Ophtalmol 18:520–528PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Laurent Kodjikian
    • 1
    • 2
    Email author
  • Jean-Daniel Grange
    • 1
  • Stéphano Baldo
    • 3
  • Stéphanie Baillif
    • 1
  • Justus G. Garweg
    • 2
  • Michel Rivoire
    • 3
  1. 1.Department of OphthalmologyCroix-Rousse HospitalLyonFrance
  2. 2.Department of Ophthalmology, InselspitalBern UniversityBernSwitzerland
  3. 3.Department of SurgeryCentre Léon BérardLyonFrance

Personalised recommendations